Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

This next-gen weight-loss drug offers a new hope — and a bonus Ozempic and Wegovy don’t have

The once-weekly shot may be a tempting alternative to popular GLP-1 class drugs like Ozempic and Wegovy

The Independent UK

On the same day as his ‘fat jab’ launch, Trump issued new reason to deny visas to foreigners: obesity

The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in benefits

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

Benzinga

Trump Unveils 'TrumpRx' Program Slashing Prices of Wegovy and Zepbound

Trump launches "TrumpRx" program to cut prices of Wegovy and Zepbound, making weight-loss drugs more affordable for Americans.

International Business Times

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Trump announces plan to cut cost of weight loss drugs and expand access

Injectable versions of GLP-1s from Eli Lilly and Novo Nordisk will see reduced prices and broader coverage

The Guardian - US

Trump says Medicare can now cover weight loss drugs like Ozempic

The pilot program could make it easier for seniors to use drugs like Wegovy and Zepbound.

Axios

Trump announces plans to slim down cost of popular weight-loss drugs to $149 a month

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan

The Independent UK

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.

Benzinga

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

The Guardian - UK

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly just posted its fastest revenue growth ever, putting shares up 40% in less than three months. The stock continues to have strong long-term potential.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose

Axios

Trump close to deal to allow Medicare coverage of weight loss drugs

A deal could significantly expand seniors' access to the popular drugs.

Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Barchart

Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

The Independent UK

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Guardian - UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

Benzinga

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

International Business Times

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.